Multiple Myeloma (MM) is a haematological malignancy characterised by the uncontrolled proliferation of mutated plasma cells in the bone marrow. In Hong Kong, there are about 300 new cases per year. Very often, patients with MM are presented with anaemia, osteolytic bone disease, and acute kidney injury, leading to severe complications if left untreated. Fortunately, a plethora of treatment regimens have emerged in the past decade, providing patients with better disease control and survival opportunities.
On 11th July 2023, the Hong Kong Society of Myeloma (HKSOM), together with the Macao Laboratory Medicine Association, organised a hybrid webinar themed “Insights on Multiple Myeloma” in Hyatt Regency Hong Kong. Dr. Chim Chor Sang, James, Founder and Chairman of HKSOM, commenced the symposium with a welcome speech. Then, Prof. Michel Delforge, Clinical Head of the Department of Haematology at the University Hospital Leuven, shared his practical insights into MM treatment strategies. After the Q&A session, Dr. Adela Lam, a haematology specialist, made an opening speech for the case sharing session and introduced the speaker, Dr. Ngai Cheong, Michael, a Resident at the Department of Medicine at Queen Mary Hospital, who shared his cases of post-ASCT lenalidomide maintenance. Following the case sharing were another Q&A session and dinner.
Dr. Chim made an opening speech and introduced the topic of the webinar.
Prof. Delforge shared his treatment strategies of multiple myeloma.
Dr. Adela Lam during the opening of case sharing session.
Dr. Ngai presented the clinical data and a case on post-ASCT lenalidomide maintenance.
Audience in Macau joined the meeting virtually from Grand Lisboa Hotel.
